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CMMC

:   colonic migrating motor complex

EJPs

:   excitatory junction potentials

ENS

:   enteric nervous system

fIJPs

:   fast inhibitory junction potentials

iNOS

:   inducible NOS

IR

:   immunoreactive

L‐NNA

:   N^ω^‐nitro‐L‐arginine

nNOS

:   neuronal NOS

sIJPs

:   slow inhibitory junction potentials

SNP

:   sodium nitroprusside

Tables of Links {#bph13646-sec-0005}
===============

**TARGETSGPCRs** ^*a*^[Muscarinic receptors](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=14)[P2Y~1~ receptors](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323)**Enzymes** ^*b*^n[NOS, neuronal NOS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1251)**LIGANDS**[Atropine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320)[Carbachol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298)[Nicardipine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2559)[L‐NNA, N^ω^‐nitro‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8759)[MRS2500](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1724)[Oxaliplatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7433)[^1]

Introduction {#bph13646-sec-0006}
============

Oxaliplatin, usually administered together with 5‐fluorouracil and leucovorin, is a third generation platinum‐based agent used as the first line of treatment for tumours resistant to the first and second generation platinum‐based agents, cisplatin and carboplatin (Raymond *et al.,* [1998](#bph13646-bib-0040){ref-type="ref"}). Combinations containing oxaliplatin have shown great therapeutic potential, improving progression‐free and overall survival rates of patients with colorectal cancer (André *et al.,* [2004](#bph13646-bib-0003){ref-type="ref"}; De Gramont *et al.,* [2007](#bph13646-bib-0015){ref-type="ref"}).

Oxaliplatin exerts its cytotoxic effects via formation of platinum‐DNA adducts that trigger immobilization of the mitotic cell cycle and stimulate apoptosis of dividing cells (Graham *et al.,* [2000](#bph13646-bib-0022){ref-type="ref"}; Goodisman *et al.,* [2006](#bph13646-bib-0020){ref-type="ref"}). At clinically recommended doses, oxaliplatin is reported to be less toxic for the auditory, haematological and renal systems than cisplatin and carboplatin (Raymond *et al.,* [1998](#bph13646-bib-0040){ref-type="ref"}). However, oxaliplatin‐induced neurotoxicity differs from that induced by other platinum compounds, triggering both acute and delayed peripheral neuropathies as well as gastrointestinal dysfunctions (Stojanovska *et al.,* [2015](#bph13646-bib-0056){ref-type="ref"}).

Gastrointestinal side‐effects are a predominant cause of dose limitation, presenting a constant challenge for efficient and tolerable treatment of cancer (Verstappen *et al.,* [2003](#bph13646-bib-0060){ref-type="ref"}; McQuade *et al.,* [2014](#bph13646-bib-0033){ref-type="ref"}). About 40% of patients receiving standard dose chemotherapy and nearly all patients receiving high dose chemotherapy exhibit pain, ulceration, bloating, vomiting, diarrhoea and/or constipation throughout the course of treatment (McQuade *et al.,* [2014](#bph13646-bib-0033){ref-type="ref"}). Platinum‐based agents specifically are linked to a heightened incidence of gastrointestinal side‐effects with up to 90% of patients experiencing vomiting, nausea and/or diarrhoea during the course of treatment (Sharma *et al.,* [2005](#bph13646-bib-0052){ref-type="ref"}). Addition of platinum‐based chemotherapeutics to combination regimes (such as FOLFOX -- a combination of 5‐fluorouracil, leucovorin and oxaliplatin) increases the incidence of chronic diarrhoea and treatment‐related death (Souglakos *et al.,* [2006](#bph13646-bib-0054){ref-type="ref"}). Gastrointestinal side‐effects can persist up to 10 years after the treatment has ceased (Denlinger and Barsevick, [2009](#bph13646-bib-0016){ref-type="ref"}).

Gastrointestinal functions are controlled by the enteric nervous system (ENS) embedded in the wall of the gastrointestinal tract (Furness, [2012](#bph13646-bib-0019){ref-type="ref"}). Damage to the ENS underlies gastrointestinal dysfunction in many pathophysiological conditions (Furness, [2012](#bph13646-bib-0019){ref-type="ref"}). To date, few studies have investigated the effects of platinum‐based chemotherapeutics on enteric neurons in animal models (Vera *et al.,* [2011](#bph13646-bib-0059){ref-type="ref"}; Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}; Pini *et al.,* [2016](#bph13646-bib-0037){ref-type="ref"}). These studies reported significant reductions in the number of myenteric neurons in the colon and stomach, alongside altered expression of neuronal NOS (nNOS) following *in vivo* treatment with cisplatin (Vera *et al.,* [2011](#bph13646-bib-0059){ref-type="ref"}; Pini *et al.,* [2016](#bph13646-bib-0037){ref-type="ref"}) and oxaliplatin (Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}). These changes in the ENS are correlated with reductions in gastrointestinal transit and colonic propulsive activity in oxaliplatin‐treated animals, which may be related to symptoms of constipation or diarrhoea.

NO, synthesizedby the NOS enzymes, is a highly reactive and widely distributed transmitter found throughout both the central and peripheral nervous systems. In the gastrointestinal tract, NO is a well‐established mediator of vasodilation and gastrointestinal relaxation (Takahashi, [2003](#bph13646-bib-0057){ref-type="ref"}; Bornstein *et al.,* [2004](#bph13646-bib-0006){ref-type="ref"}). Two types of NOS participate in normal physiological responses, nNOS localized to neurons and endothelial NOS (eNOS) localized to the endothelium. Increased expression of inducible NOS (iNOS) occurs during times of cellular stress. Neurons containing nNOS are the primary source of NO in the ENS and represent approximately 30% of the neuronal population in the myenteric plexus of the mouse small intestine and colon (Qu *et al.,* [2008](#bph13646-bib-0038){ref-type="ref"}; Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}). In enteric ganglia, nNOS is expressed by descending interneurons and by inhibitory motor neurons supplying the intestinal smooth muscle (Lecci *et al.,* [2002](#bph13646-bib-0030){ref-type="ref"}). Moreover, a myogenic nNOS isoform is expressed by gastrointestinal smooth muscle cells (Daniel *et al.,* [2000](#bph13646-bib-0014){ref-type="ref"}). NO released from both neurons and smooth muscle is essential for sphincter relaxation and generation of complex gastrointestinal motor patterns, which contribute to propulsion during digestion (Sarna *et al.,* [1993](#bph13646-bib-0049){ref-type="ref"}; Roberts *et al.,* [2007](#bph13646-bib-0046){ref-type="ref"}; Roberts *et al.,* [2008](#bph13646-bib-0045){ref-type="ref"}). Altered expression of nNOS in the ENS has been linked to several pathological conditions, and increased levels of nNOS in the ENS can be indicative of oxidative stress (Rivera *et al.,* [2011a](#bph13646-bib-0042){ref-type="ref"}). The effects of oxidative stress on post mitotic cells, including enteric neurons, can be cumulative, resulting in neuronal loss and deterioration of neuronal function impairing gastrointestinal motility patterns (Chandrasekharan *et al.,* [2011](#bph13646-bib-0011){ref-type="ref"}). The role of oxidative stress in chemotherapy‐induced gastrointestinal dysfunction has not been explored. This study investigated the role of oxidative stress in enteric neuronal damage and colonic dysmotility caused by *in vivo* oxaliplatin treatment.

Methods {#bph13646-sec-0007}
=======

Animals {#bph13646-sec-0008}
-------

All animal care and experimental procedures were approved by the Victoria University Animal Experimentation Ethics Committee and performed in accordance with the guidelines of the National Health and Medical Research Council Australian Code of Practice for the Care and Use of Animals for Scientific Purposes*.* Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny *et al.*, [2010](#bph13646-bib-0029){ref-type="ref"}; McGrath and Lilley, [2015](#bph13646-bib-0031){ref-type="ref"}).

Male Balb/c mice aged 6--8 weeks (18--25 g) supplied from the Animal Resources Centre (Perth, Australia) were used for all experiments. Mice had free access to food and water and were kept under a 12 h light/dark cycle in a well‐ventilated room at an approximate temperature of 22°C. Mice acclimatized for a minimum of 5 days and a maximum of 7 days prior to the commencement of *in vivo* intraperitoneal injections. A total of 70 mice were used for this study.

In vivo oxaliplatin injections {#bph13646-sec-0009}
------------------------------

Mice were randomly assigned into two groups: oxaliplatin‐treated and sham‐treated. Mice received intraperitoneal injections of oxaliplatin (Tocris Bioscience, UK), 3 mg·kg^−1^ per dose, 3 times a week via a 26 gauge needle. Oxaliplatin was dissolved in sterile water in order to make 10^−2^ M·L^−1^ stock solutions and refrigerated at −20°C. The stock was then defrosted and further diluted with sterile water to make 10^−3^ M·L^−1^ solutions for injections. The oxaliplatin dose was calculated to be equivalent to standard human dose per body surface area (Renn *et al.,* [2011](#bph13646-bib-0041){ref-type="ref"}). Sham‐treated mice received sterile water via intraperitoneal injection 3 times a week via a 26 gauge needle. The volume injected did not exceed 200 μL per injection. Mice were killed via cervical dislocation 14 days after the first injection. Colons were collected for *in vitro* experiments.

Assessment of mitochondrial superoxide production {#bph13646-sec-0010}
-------------------------------------------------

MitoSOX™ Red M36008 (Invitrogen, Australia) was used to visualize mitochondrially‐derived superoxide in whole‐mount preparations of submucosal and myenteric ganglia of the distal colon. Freshly excised distal colon preparations were dissected to expose submucosal and myenteric ganglia. Preparations were incubated in oxygenated physiological saline with MitoSOX™ Red M36008 (5 μM) in a gently shaking incubator Unimax 1010 (Heidolph Instruments, Germany) at a constant temperature of 37°C for 40 min. Tissues were washed (2 × 30 min) with oxygenated physiological saline (composition in mM: NaCl 118, KCl 4.6, CaCl~2~ 3.5, MgSO~4~ 1.2, NaH~2~PO~4~ 1, NaHCO~3~ 25 and d‐Glucose 11; bubbled with 95%O~2~ and 5% CO~2~) and fixed in 4% paraformaldehyde overnight at 4°C. The following day tissues were washed (2 × 30 min) with physiological saline and mounted on glass slides with DAKO fluorescent mounting medium for imaging. All images were captured at identical acquisition exposure‐time conditions, calibrated to standardized minimum baseline fluorescence, converted to binary and changes in fluorescence from baseline were measured in arbitrary units (arb. units) using Image J software (NIH, MD, USA). The corrected total fluorescence was calculated as previously described (Burgess *et al.,* [2010](#bph13646-bib-0008){ref-type="ref"}) in 32 5 × 5 μm^2^ boxes within myenteric ganglia from each preparation to exclude fluorescence outside the ganglia.

Mitochondrial membrane potential assay {#bph13646-sec-0011}
--------------------------------------

Mitochondrial membrane potential changes in cells may be detected with the cationic, lipophilic JC‐10 dye. In normal cells, JC‐10 concentrates in the mitochondrial matrix where it forms red fluorescent aggregates (JC aggregates). In contrast, apoptotic cells stain in green fluorescent colour (JC monomeric form) due to the JC‐10‐labelled release of cytochrome *c* diffusing out of the mitochondria as a result of mitochondrial depolarisation and increased permeability. JC‐10 fluorescent mitochondrial membrane potential microplate assay kit (Abcam, MA, USA) was used to detect mitochondrial membrane potential changes, and the release of cytochrome *c* from damaged mitochondria in the myenteric ganglia of the distal colon. Freshly excised distal colon preparations from sham and oxaliplatin‐treated mice were bathed in oxygenated physiological saline and dissected to expose the myenteric ganglia. Immediately following dissection, preparations were incubated for 20 min with 500 μL of JC‐10 dye solution (buffer A) in a gently shaking incubator Unimax 1010 (Heidolph Instruments, Germany) at a constant temperature of 37°C. After 20 min, 500 μL of buffer B solution was added to tissue preparations and allowed to incubate for another 20 min in a gently shaking incubator at a constant temperature of 37°C. Immediately following final incubation, tissues were mounted on glass slides with DAKO fluorescent mounting medium for imaging under a Nikon Eclipse Ti laser scanning microscope (Nikon, Japan).

Immunohistochemistry {#bph13646-sec-0012}
--------------------

Collected tissues (distal and proximal colon) were placed in oxygenated PBS (pH 7.2) containing nicardipine (3 μM) (Sigma‐Aldrich, Australia) for 20 min to inhibit smooth muscle contraction. Samples were cut open along the mesenteric border, cleared of their contents, maximally stretched and dissected mucosa down to expose either the submucosal plexus (distal colon) or myenteric plexus (distal and proximal colon). Tissues were then fixed with Zamboni\'s fixative (2% formaldehyde, 0.2% picric acid) overnight at 4°C. Preparations were cleared of fixative by washing three times for 10 min with DMSO (Sigma‐Aldrich, Australia) followed by 3 × 10 min washes with PBS. Fixed tissues were stored at 4°C in PBS for a maximum of 5 days.

Whole‐mount preparations were incubated with 10% normal donkey serum (Chemicon, USA) for 1 h at room temperature. Tissues were then washed (2 × 5 min) with PBS and incubated with primary antibodies against β‐tubulin class III (TuJ1) (chicken, 1:1000, Abcam, MA, USA), nitrotyrosine (rabbit, 1:1000, Millipore, CA, USA), nNOS (goat, 1:500, Abcam, MA, USA) and cleaved caspase‐3 (rabbit, 1:500, Cell Signalling Technologies, MA, USA) overnight at 4°C. Tissues were then washed in PBS (3 × 10 min) before incubation with species‐specific secondary antibodies labelled with different fluorophores: donkey anti‐chicken Alexa 594 (1:200, Jackson Immuno research Laboratories, PA, USA), donkey anti‐goat Alexa 488 (1:200, Jackson Immuno research Laboratories, PA, USA) and donkey anti‐rabbit Alexa 488 and 647 (1:200, Jackson Immuno research Laboratories, PA, USA) for 2 h at room temperature. Double immunohistochemical labelling was performed using mixtures of antibodies raised in different species and using species specific secondary antibodies labelled with different fluorophores. Tissues were given a further 3 × 10 min washes with PBS, followed by a 2 min incubation with the fluorescent nucleic acid stain, 4′‐6‐diamidino‐2‐phenylindole (DAPI; 14 nM) (Invitrogen, Australia). Whole‐mount preparations were given three final 10 min washes in PBS and then mounted on glass slides using fluorescent mounting medium (DAKO, Australia). Whole‐mount preparations were observed under a Nikon Eclipse Ti laser scanning microscope (Nikon, Japan); eight randomly chosen images from each preparation were captured with a 20× objective and processed using NIS Elements software (Nikon, Japan). The numbers of β‐tubulin‐immunoreactive (IR) neurons, nNOS‐IR neurons and neurons displaying translocation of nitrated proteins to the nuclei were quantified in both submucosal and myenteric ganglia within a 2 mm^2^ area of each distal colon preparation. Proximal colon preparations were use to quantify the numbers of β‐tubulin‐IR and nNOS‐IR neurons. Images were then calibrated to standardized minimum baseline fluorescence, converted to binary, and changes in caspase‐3 fluorescence were detected using Image J software (NIH, MD, USA). Quantitative analyses were conducted blindly.

Histology {#bph13646-sec-0013}
---------

The distal colon was harvested and placed in a 10% formalin solution overnight and then transferred into 70% ethanol the following day. Paraffin embedded colon sections were cut 5 μm thick and de‐waxed in a 60°C oven for 30 min. To examine the morphological changes to the colon, a standard haematoxylin and eosin staining protocol was followed (26, 27). Ten sections per preparation were analysed. All images were analysed blindly.

Imaging {#bph13646-sec-0014}
-------

Three dimensional (z‐series) images of wholemount preparations were taken using a Nikon Eclipse Ti laser scanning microscope (Nikon, Japan. Fluorophores were visualized using excitation filters for Alexa 594 Red (excitation wavelength 559 nm), Alexa 488 (excitation wavelength 473 nm) and Alexa 405 (excitation wavelength 405 nm). Z‐series images were taken at step size of 1.75 μm (1600 × 1200 pixels).

Western blotting {#bph13646-sec-0015}
----------------

The whole colon was harvested, cut along the mesenteric border and pinned mucosa side up to a silicone‐based petri dish containing physiological saline. The colon was flushed of its contents, and the mucosa, submucosa and the circular muscle layers were dissected and discarded. The remaining longitudinal muscle‐myenteric plexus (LMMP) whole‐mount preparations were then snap frozen using liquid nitrogen.

Frozen tissues were homogenized with a Polytron homogeniser (Kinematica AG, Lucerne, Switzerland) for 20 s in ice‐cold WB buffer (40 mM Tris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% Triton X‐100; 25 mM β‐glycerophosphate; 25 mM NaF; 1 mM Na3VO4; 10 μg·mL^−1^ leupeptin; and 1 mM PMSF), and the whole homogenate was used for Western blot analysis. Sample protein concentrations were determined with a DC protein assay kit (Bio‐Rad Laboratories, Hercules, CA, USA), and equivalent amounts of protein from each sample were dissolved in Laemmli buffer and subjected to electrophoretic separation on SDS‐PAGE acrylamide gels. Following electrophoretic separation, proteins were transferred to a PVDF membrane, blocked with 5% powdered milk in Tris‐buffered saline containing 0.1% Tween 20 (TBST) for 1 h followed by an overnight incubation at 4°C with rabbit anti‐iNOS primary antibody (D6B6S, Cell Signalling Technology, Danvers, MA, USA) dissolved in TBST containing 1% BSA. The following day membranes were washed for 30 min in TBST and then probed with a peroxidase‐conjugated anti‐rabbit secondary antibody (Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature. Following 30 min of washing in TBST, the blots were developed with a DARQ CCD camera mounted to a Fusion FX imaging system (Vilber Lourmat, Germany) using ECL Prime reagent (Amersham, Piscataway, NJ, USA). Densitometric measurements of the protein of interest were carried out using Fusion CAPT Advance software (Vilber Lourmat, Germany). Membranes were then stained with Coomassie Blue, scanned and total protein loaded quantified using Image J software. The signal intensity of the protein of interest was normalized to the signal for total protein loaded.

Intracellular recordings {#bph13646-sec-0016}
------------------------

Segments of the distal colon proximal to the pelvic brim were collected from day 14 sham and oxaliplatin‐treated mice and placed in physiological saline bubbled with 95% O~2~ and 5% CO~2~ at room temperature. The physiological saline contained the L‐type Ca^2^⁺ channel blocker nicardipine (3 μM) (Sigma‐Aldrich, Australia) to limit contractions. The distal colon was opened along the mesenteric border and pinned in a Sylgard‐lined (Dow Corning, USA) Petri dish. The mucosa and submucosa were removed revealing the circular muscle layer. A 20 mm long, full circumference segment was transferred into a Sylgard‐lined recording chamber and pinned with 50 μm gold‐plated tungsten pins. The recording chamber was placed on the stage of an inverted microscope fitted with fluorescent optics (Zeiss Axiovert 200), and was continuously superfused with physiological saline (3 mL·min^−1^) pre‐heated to yield a bath temperature of 35°C. Following 2 h recovery from dissection (Carbone *et al.,* [2012](#bph13646-bib-0009){ref-type="ref"}), circular smooth muscle cells were impaled with conventional intracellular borosilicate glass capillary electrodes filled with 5% 5,6‐carboxyfluorescein in 20 mM Tris buffer (pH 7.0) in 1 M KCl. Electrode resistances ranged from 60--120 MΩ. Recordings were made using an Axoclamp 2B amplifier (Axon Instruments, USA), digitised at 1--10 kHz via a Digidata 1440A interface (Molecular Devices, USA) and stored using PClamp 10.0 (Molecular Devices) on a PC. Carboxyfluorescein‐labelled cells were identified as circular muscle cells *in situ* from their morphology (Carbone *et al.,* [2012](#bph13646-bib-0009){ref-type="ref"}). Intracellular hyperpolarising current pulses (duration 500 ms, intensity 100--500 pA) were used to determine input resistance (*R* ~in~). A tungsten electrode (10--50 mm tip diameter, placed 1 mm circumferential to the recording microelectrode) was connected to an ISO‐Flex stimulator controlled by a Master‐8 pulse generator (AMPI, Israel). Single pulse stimuli (20 V, 0.4 ms duration) and short trains of high frequency pulses (20 V, 3 pulses, 40 ms interval, 0.4 ms duration) were used to activate nerve fibres. Junction potential responses were recorded in the impaled smooth muscle cells. Responses in 3--4 cells were averaged per test condition, in each animal. Data were analysed using AxoGraph 10 software.

Contraction force {#bph13646-sec-0017}
-----------------

Freshly excised distal colon was cut into 3 mm rings, cleaned of connective tissue and fat and then placed in a custom built organ‐bath chamber containing physiological saline oxygenated with 95% O~2~ and 5% CO~2~ and maintained at a constant temperature of 37°C and pH of 7.4. Colonic rings were mounted between two small metal hooks attached to force displacement transducers (Zultek Engineering, Australia), and stretched to a resting tension of 0.2 g. After 30 min, rings were returned to resting tension and allowed to stabilize for 2 h with physiological saline changed every 20 min (Habiyakare *et al.,* [2014](#bph13646-bib-0024){ref-type="ref"}). Following stabilization, 10 μM sodium nitroprusside (SNP) was added to organ bath. Baseline values were obtained by averaging 60 s of data 5 min prior to drug application; maximum relaxation was calculated as absolute change from the baseline values.

Colonic motility experiments {#bph13646-sec-0018}
----------------------------

The entire colon was removed from day 14 sham and oxaliplatin‐treated mice and set up in organ‐bath chambers to record motor patterns *in vitro* (Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}). Briefly, the colon was placed into warmed (35°C), oxygenated physiological saline until the faecal pellets were expelled. The empty colon was cannulated at both ends and arranged horizontally in organ‐bath chambers. The proximal end of the colon was connected to a reservoir containing oxygenated physiological saline to maintain intraluminal pressure. The distal end was attached to an outflow tube that provided a maximum of 2 cm H~2~O back‐pressure. Organ baths were continuously superfused with oxygenated physiological saline solution, and preparations were left to equilibrate for 30 min. Contractile activity of each segment was recorded with a Logitech Quickcam Pro camera positioned 7--8 cm above the preparation. Videos (2 × 20 min) of each test condition were captured and saved in *avi* format using VirtualDub software (version 1.9.11).

Colonic migrating motor complexes (CMMCs) were defined as propagating contractions directed from the proximal to the distal end of the colon, which travelled more than 50% of the colon length (Roberts *et al.,* [2007](#bph13646-bib-0046){ref-type="ref"}; Roberts *et al.,* [2008](#bph13646-bib-0045){ref-type="ref"}). Contractions that propagated less than 50% of the length of the colon were considered to be short contractions. Another form of incomplete contraction was identified as fragmented contractions occurring simultaneously at different parts of the colon rather than propagating over the length of the colon. Recordings were used to construct spatiotemporal maps using in‐house edge detection software (Gwynne *et al.,* [2004](#bph13646-bib-0023){ref-type="ref"}). Spatiotemporal maps plot the diameter of the colon at all points during the recording allowing contractile motor patterns to be analysed with Matlab software (version 12).

Faecal water content and colonic faecal content {#bph13646-sec-0019}
-----------------------------------------------

Wet weight of faecal pellets was measured immediately upon pellet expulsion. Pellets were then dehydrated for 72 h at room temperature prior to measurement of the dry weight. Water content was calculated as the difference between the wet weight and dry weight. Total number of faecal pellets along the entire length of the colon was counted in freshly excised intact colons from day 14 sham and oxaliplatin‐treated mice.

Data and statistical analysis {#bph13646-sec-0020}
-----------------------------

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis *et al.,* [2015](#bph13646-bib-0012){ref-type="ref"}). Data are presented as mean ± SEM. Sample size was calculated based on our previous studies on the enteric neuropathy and intestinal dysmotility associated with chemotherapy (Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}; McQuade *et al.,* [2016](#bph13646-bib-0034){ref-type="ref"}). To detect a 30% change at a power 0.8 and α = 0.05 with 10% SD, the effect size should be minimum *n* = 5 animals per group as calculated by the GPOWER program. Data were assessed using two‐way ANOVA, Welch\'s two‐tailed *t*‐test and Student\'s two‐tailed *t*‐test. Analyses were performed using Graph Pad Prism (Graph Pad Software Inc., CA, USA). Differences between group means were considered statistically significant at *P* \< 0.05.

Materials {#bph13646-sec-0021}
---------

MRS2500 \[(1R,2S,4S,5S)‐4‐\[2‐iodo‐6‐(methylamino)purin‐9‐yl\]‐2‐phosphonooxy‐1‐bicyclo \[3.1.0\]hexanyl\]methyl dihydrogen phosphate ) was from Tocris, UK; atropine, carbachol, N^ω^‐nitro‐L‐arginine (L‐NNA), nicardipine and SNP were all from Sigma‐Aldrich, Australia. These compounds were prepared as stock solutions and diluted in physiological saline daily before addition to preparations.

Results {#bph13646-sec-0022}
=======

Loss of enteric neurons and increase in subpopulations of nNOS‐immunoreactive neurons following oxaliplatin treatment {#bph13646-sec-0023}
---------------------------------------------------------------------------------------------------------------------

To investigate changes to the total number of myenteric neurons, whole‐mount preparations of the distal and proximal colon were labelled with β‐tubulin antibody to count neurons within a 2 mm^2^ area (Figure [1](#bph13646-fig-0001){ref-type="fig"}). Repeated *in vivo* administration of oxaliplatin caused myenteric neuronal loss in both the proximal and distal colon when compared to sham (Figure [2](#bph13646-fig-0002){ref-type="fig"}A). Significant neuronal loss was also observed in the submucosal plexus in the distal colon from oxaliplatin‐treated mice, compared to sham (Figure [2](#bph13646-fig-0002){ref-type="fig"}A^I^).

![Whole‐mount preparations of myenteric neurons in the proximal and distal colon following 14 days of *in vivo* oxaliplatin treatment. Myenteric neurons labelled with anti‐β‐tubulin III antibody (Tub III, red) counterstained with DAPI (blue) that labels neuronal nuclei within the ganglion (arrow) and smooth muscle cell nuclei outside the ganglion (arrowhead) (C^I^). nNOS‐IR neurons (green). Scale bar = 20 μm.](BPH-173-3502-g001){#bph13646-fig-0001}

![Effect of *in vivo* oxaliplatin treatment on total number of neurons and average number and proportion of nNOS‐IR enteric neurons. Average number of myenteric neurons in the proximal and distal colon and submucosal neurons was counted per 2 mm^2^ in the distal colon from day 14 sham and oxaliplatin‐treated mice (A,A^I^). Average number of nNOS‐IR neurons (B,B^I^) in myenteric and submucosal ganglia counted within 2 mm^2^ area. Proportion of nNOS‐IR neurons to the total number of myenteric and submucosal neurons (C,C^I^). Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group per time point.](BPH-173-3502-g002){#bph13646-fig-0002}

To determine if oxaliplatin administration was associated with changes in subpopulations of myenteric neurons, inhibitory muscle motor and interneurons IR for nNOS were analysed. Fewer nNOS‐IR neurons were observed in the myenteric plexus of the both the proximal and distal colon following oxaliplatin administration when compared with sham (Figure [2](#bph13646-fig-0002){ref-type="fig"}B), but not in the submucosal plexus. The proportion of nNOS‐IR neurons was, however, significantly increased in the myenteric and submucosal plexus of the distal colon, but not the myenteric plexus of the proximal colon from oxaliplatin‐treated mice, when compared to sham‐treated mice (Figure [2](#bph13646-fig-0002){ref-type="fig"}C,C^I^).

Reactive oxygen species, iNOS expression and protein nitration in the submucosal and myenteric ganglia of the colon following in vivo oxaliplatin treatment {#bph13646-sec-0024}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

To evaluate production of ROS following long‐term oxaliplatin treatment, distal colon samples were probed with a fluorescent mitochondrial superoxide marker MitoSOX™ Red M36008. Increased MitoSOX fluorescence was found in both the submucosal (Figure [3](#bph13646-fig-0003){ref-type="fig"}A,A^I^ and B,B^I^) and myenteric (Figure [3](#bph13646-fig-0003){ref-type="fig"}C,C^I^ and D,D^I^) plexuses of the distal colon from oxaliplatin‐treated mice compared to sham‐treated animals (Figure [3](#bph13646-fig-0003){ref-type="fig"}E).

![Mitochondrial superoxide in the colonic submucosal and myenteric ganglia and iNOS protein expression. Fluorescent and binary images of wholemount preparations of submucosal (A,A^I^ and B,B^I^) and myenteric (C,C^I^ and D,D^I^) ganglia labelled with MitoSOX™ Red in the colons from day 14 sham and oxaliplatin‐treated mice. Scale bar = 50 μm. (E) Quantification of the levels of mitochondrial superoxide production visualized by fluorescent probe in submucosal and myenteric ganglia in colonic preparations from day 14 sham and oxaliplatin‐treated animals. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group. (F) Representative images and quantification of the Western blot analysis for iNOS in LMMP tissue from day 14 sham and oxaliplatin‐treated mice. iNOS protein was normalized to total protein values obtained from the Coomassie Blue membrane staining (see Methods section). All values are expressed as a percentage of the values obtained from sham‐treated mice. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 5 mice per group.](BPH-173-3502-g003){#bph13646-fig-0003}

Western blot analysis revealed a 40% increase in the expression of iNOS in LMMP preparations from the colon of oxaliplatin‐treated mice (*n* = 5 mice/group, Figure [3](#bph13646-fig-0003){ref-type="fig"}F).

An antibody against nitrotyrosine was used to label nitrated proteins within the submucosal (Figure [4](#bph13646-fig-0004){ref-type="fig"}A--A^II^ and B--B^II^) and myenteric (Figure [4](#bph13646-fig-0004){ref-type="fig"}C--C^II^ and D--D^II^) plexuses. The number of neurons per 2 mm^2^ displaying translocation of nitrated proteins to the nuclei was higher in both the submucosal and myenteric plexuses of the colon from oxaliplatin‐treated ,compared with sham‐treated (Figure [4](#bph13646-fig-0004){ref-type="fig"}E).

![Translocation of nitrotyrosine to the nuclei of submucosal and myenteric neurons. Whole‐mount preparations of colonic submucosal ganglia from day 14 sham (A--A^II^) and oxaliplatin‐treated (B--B^II^) mice and myenteric ganglia from sham (C--C^II^) and oxaliplatin‐treated (D--D^II^) mice. Scale bar = 50 μm. Neurons and ganglia were labelled with anti‐β‐tubulin III antibody (Tub III, red). Nitrotyrosine within the ganglia was labelled with anti‐nitrotyrosine antibody (NT, green). \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group.](BPH-173-3502-g004){#bph13646-fig-0004}

Apoptosis of submucosal and myenteric neurons in the colon {#bph13646-sec-0025}
----------------------------------------------------------

Diffusion of cytochrome *c* out of the mitochondria as a result of mitochondrial membrane depolarisation and increased permeability was measured via fluorescence (green) of monomeric JC‐10. Increased monomeric JC‐10 fluorescence was found in both submucosal (Figure [5](#bph13646-fig-0005){ref-type="fig"}A,A^I^ and B,B^I^) and myenteric (Figure [5](#bph13646-fig-0005){ref-type="fig"}C,C^I^ and D,D^I^) plexuses of the distal colon from oxaliplatin‐treated mice compared with sham‐treated animals (Figure [5](#bph13646-fig-0005){ref-type="fig"}E). Both tissues from both sham and oxaliplatin‐treated mice experienced the same dissection and therefore the same level of cellular stress associated with dissection. Cellular stress associated with dissection can induce short‐term mitochondrial depolarisation, resulting in modest increases in JC‐10 fluorescence in tissues from both sham and oxaliplatin‐treated mice. However, the level of JC‐10 fluoresce in tissue from oxaliplatin‐treated mice was significantly higher (Figure [5](#bph13646-fig-0005){ref-type="fig"}) due to long‐term mitochondrial depolarisation associated with neurotoxicity.

![Changes in neuronal mitochondrial membrane potential indicative of cytochrome *c* release in submucosal and myenteric plexuses. Fluorescent and binary wholemount preparations of submucosal (A,A^I^ and B,B^I^) and myenteric (C,C^I^ and D,D^I^) ganglia labelled with JC‐10 dye in the colons from day 14 sham and oxaliplatin‐treated mice. Green fluorescent colour (JC monomeric form) is due to the JC‐10‐labelled release of cytochrome *c* diffusing out of the mitochondria as a result of mitochondrial depolarisation and increased permeability. Scale bar = 50 μm. (E) Quantification of the levels of monomeric JC‐10 production visualized by fluorescent probe in submucosal and myenteric ganglia in colonic preparations from sham and oxaliplatin‐treated animals. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group.](BPH-173-3502-g005){#bph13646-fig-0005}

Caspase‐3 immunoreactivity was absent in both the submucosal and myenteric ganglia in the colon preparations from sham‐treated mice, but was observed in both the submucosal and myenteric ganglia in the colon preparations from oxaliplatin‐treated mice indicating neuronal apoptosis (not shown, *n* = 6 mice/group). Caspase‐3 labelling appeared both within the neuronal cell body as well as smaller, irregular patches of apoptotic debris that did not colocalise with β‐tubulin III immunoreactivity.

Effects of oxaliplatin treatment on neuromuscular transmission in the colon {#bph13646-sec-0026}
---------------------------------------------------------------------------

Neuromuscular transmission in the distal colon was investigated using intracellular electrophysiology. Electrical stimulation of nerve fibres innervating the circular muscle in distal colon segments evoked junction potentials in single smooth muscle cells that were defined as fast inhibitory junction potentials (fIJPs), slow inhibitory junction potentials (sIJPs) and excitatory junction potentials (EJPs) using pharmacological blockers.

In control physiological saline, the resting membrane potential (RMP) of smooth muscle cells from sham‐treated mice averaged −38 ± 1.0 mV (*n* = 6 mice) and did not differ from that of smooth muscle cells from oxaliplatin‐treated mice (−39 ± 1.0 mV, *n* = 6 mice). RMPs in both groups were unaffected by the selective P2Y~1~ receptor antagonist MRS2500 (1 μM) (sham: −39 ± 1.4 mV, oxaliplatin: −37 ± 1.3 mV), L‐NNA (1 mM) (sham: −39 ± 1.3 mV, oxaliplatin: −38 ± 0.9 mV) or the muscarinic antagonist, atropine (1 μM) (sham: −38 ± 1.4 mV, oxaliplatin: −41 ± 3.3 mV). The input resistance of smooth muscle cells from sham‐treated mice averaged 8.3 ± 0.9 MΩ (*n* = 6 mice) in control physiological saline; this did not differ significantly from the input resistance of smooth muscle cells from oxaliplatin‐treated mice (8.7 ± 1.0 MΩ, *n* = 6 mice).

Single pulse and compound stimuli (trains of 20 V, 40 ms interval, 0.4 ms pulse duration) evoked fIJPs in colonic smooth muscle cells (Figure [6](#bph13646-fig-0006){ref-type="fig"}A, A^I^). The amplitudes of fIJPs recorded in smooth muscle cells from the distal colon of sham‐treated mice following a 20 V compound stimulus did not differ significantly from those recorded from the distal colon of oxaliplatin‐treated mice (Figure [6](#bph13646-fig-0006){ref-type="fig"}B). The duration of fIJPs (width at half amplitude) was not different between (sham: 397 ± 17 ms) and oxaliplatin‐treated (422 ± 27 ms) groups. The amplitudes of fIJPs increased with increasing stimulus strength, but no significant differences were found in responses between sham and oxaliplatin‐treated mice (Figure [6](#bph13646-fig-0006){ref-type="fig"}C). Fast IJPs were inhibited by MRS2500 (1 μM).

![Intracellular recordings of fast and sIJPs from colonic smooth muscle cells. Single pulse electrical stimulus (40 V, 0.4 ms duration) and high frequency compound stimulus (20 V, 0.04 ms interval, 0.4 ms duration) evoked fIJPs in smooth muscle cells from day 14 sham (A) and oxaliplatin‐treated (A^I^) mice (~\*~ stimulus artefact). (B) The mean amplitude of fIJPs in response to compound stimuli from smooth muscle cells of sham and oxaliplatin‐treated mice (*n* = 4 mice/group). (C) Amplitudes of fIJPs to increasing strength of the electrical stimuli (2--60 V) in smooth muscle cells of sham and oxaliplatin‐treated mice. (D) Blocking fIJPs with a selective antagonist of P2Y~1~ receptors, MRS2500 (1 μM) revealed sIJPs in smooth muscle cells from both sham and oxaliplatin‐treated mice. (E) Comparison of the amplitude of sIJPs in smooth muscle cells from sham and oxaliplatin‐treated mice. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group.](BPH-173-3502-g006){#bph13646-fig-0006}

Short compound stimuli (trains of 20 V, 3 pulses, 40 ms interval, 0.4 ms pulse duration) applied in the presence of MRS2500 evoked sIJPs (Figure [6](#bph13646-fig-0006){ref-type="fig"}D), whose amplitudes were greater in smooth muscle cells from the distal colon of mice treated with oxaliplatin than from sham‐treated mice (Figure [6](#bph13646-fig-0006){ref-type="fig"}E). The sIJPs were abolished by addition of L‐NNA (1 mM).

Short compound stimuli (trains of 20 V, 3 pulses, 40 ms interval, 0.4 ms pulse duration) of nerve fibres in the presence of both MRS2500 and L‐NNA, inhibiting fast and slow IJPs respectively, evoked EJPs (data not shown). EJPs were inhibited by atropine (1 μM). The EJPs recorded in smooth muscle cells from the distal colon of sham‐treated mice (6 ± 0.4 mV) did not differ from those of oxaliplatin‐treated mice (6 ± 0.7 mV). Atropine reduced the amplitude of responses in sham‐treated mice from 6 ± 0.4 to 0.8 ± 0.3 mV (*P* \< 0.05) and from 6 ± 0.7 to 0.8 ± 0.2 mV in oxaliplatin‐treated mice (*P* \< 0.05, *n* = 6 animals per group).

Effects of oxaliplatin treatment on colonic smooth muscles {#bph13646-sec-0027}
----------------------------------------------------------

Smooth muscle tone of the distal colon was studied in organ bath experiments using force transducers. We measured the force produced by 3 mm wide circular muscle rings. Application of SNP (10 μM) to organ baths containing distal colon segments resulted in a decrease in circular muscle tone, that is relaxation, in tissues from both sham (Figure [7](#bph13646-fig-0007){ref-type="fig"}A) and oxaliplatin‐treated (Figure [7](#bph13646-fig-0007){ref-type="fig"}A^I^) mice. The reduction in tension produced by SNP was greater in the colon segments from sham‐treated mice than in segments from oxaliplatin‐treated mice (Figure [7](#bph13646-fig-0007){ref-type="fig"}B). Thus, the relaxation force in response to SNP was reduced in colonic circular muscles from oxaliplatin‐treated mice.

![Effects of oxaliplatin treatment on colonic smooth muscles. (A,A^I^) Smooth muscle relaxation following application of the NO donor, SNP (10 μM) to the colon from day 14 sham (A) and oxaliplatin‐treated (A^I^) mice. (B) Comparison of the maximum relaxation produced by circular muscles in response to SNP in colonic preparations from sham and oxaliplatin‐treated mice quantified as an absolute change in the force transduction from the basal values. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group. (C) Resting diameter of the distal colon from sham and oxaliplatin‐treated mice. \**P =* 0.05, significantly different as indicated; *n* = 7 mice per group. (D) Gross morphological changes in the colon following repeated *in vivo* oxaliplatin administration. Colonic crypt length was shorter in oxaliplatin‐treated mice and muscle thickness was reduced in comparison to the sham‐treated animals. (D^I^) Statistical analysis of the muscle layer thickness in the colon preparations from sham and oxaliplatin‐treated mice. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 6 mice per group, 10 sections per preparation from each animal.](BPH-173-3502-g007){#bph13646-fig-0007}

The resting colon diameter measured in organ‐bath experiments between contractions was larger in preparations from mice treated with oxaliplatin (2.4 ± 0.1 mm) compared with sham‐treated mice (2.1 ± 0.1 mm) (*n* = 7 animals per group) (Figure [7](#bph13646-fig-0007){ref-type="fig"}C). Histological analysis of colon sections revealed thinning of the colonic muscle layer in oxaliplatin‐treated mice when compared with sham (Figure [7](#bph13646-fig-0007){ref-type="fig"}D). Quantitative analysis confirmed that this reduction was statistically significant (Figure [7](#bph13646-fig-0007){ref-type="fig"}D^I^).

Colonic motility {#bph13646-sec-0028}
----------------

### Colonic motor patterns {#bph13646-sec-0029}

Analysis of the total number of contractions included all types of motor patterns in the colon (CMMCs, short and fragmented contractions) (Figure [8](#bph13646-fig-0008){ref-type="fig"}A). The frequency, speed of propagation and length of contractions were measured for each specific type of motor activity.The total number and rate of rise of contractions were reduced in the colons from oxaliplatin‐treated animals compared to sham‐treated mice (*P* \< 0.05 for both, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). The addition of L‐NNA did not alter the overall number of contractions in either group (Figure [8](#bph13646-fig-0008){ref-type="fig"}B, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). Further analysis revealed differences in occurrence of various types of colonic motor patterns in the oxaliplatin‐treated group with a significant decrease in the proportion of CMMCs (*P* \< 0.05, Figure [8](#bph13646-fig-0008){ref-type="fig"}C) and increase in the proportion of fragmented contractions (*P* \< 0.05, Figure [8](#bph13646-fig-0008){ref-type="fig"}E). Application of L‐NNA restored the proportion of CMMCs in oxaliplatin‐treated colons to the levels comparable with sham‐treated colons (Figure [8](#bph13646-fig-0008){ref-type="fig"}C), but had no significant effect on the proportion of either short or fragmented contractions (Figure [8](#bph13646-fig-0008){ref-type="fig"}D,E).

![Total number of contractions and proportion of different types of contractile activity in the colon before and after application of L‐NNA. (A) Examples of spatiotemporal maps generated from digital video recordings of colonic motility from day 14 sham and oxaliplatin‐treated mice before (control) and after addition of L‐NNA. Each contraction can be seen as a reduction in the gut width (red), while relaxation as an increase in the gut width (blue). CMMCs propagate \>50% of the colon length, short contractions (SCs) propagate \<50% of the colon length and fragmented contractions (FCs) are interrupted by period(s) of relaxation during contraction. (B) The total number of contractions including all types of contractile activity in the colons from sham and oxaliplatin‐treated mice. The proportion of CMMCs (C), short contractions (D) and fragmented contractions (E) to the total number of contractions was calculated in maps from sham‐treated and oxaliplatin‐treated mice before and after addition of L‐NNA. Data are presented as an average of contractions per 10 min from a total of 40 min of video recording at baseline intraluminal pressure prior to and after the addition of L‐NNA. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 10 mice per group.](BPH-173-3502-g008){#bph13646-fig-0008}

###### 

Parameters of different types of colonic contractions

                                                                                                                    Sham‐treated (*n* = 10 mice)   Oxaliplatin‐treated (*n* = 10 mice)
  ------------------------------------------------------------- --------------------------------------------------- ------------------------------ ---------------------------------------------------
  All contractions                                                                                                                                 
  Frequency (contractions/10 min)                               Control                                             33.8 ± 2.4                     21.7 ± 2.9[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         31.6 ± 3.9                                          21.8 ± 3.9                     
  Speed (mm/s)                                                  Control                                             1.8 ± 0.1                      1.3 ± 0.2
  L‐NNA                                                         3.4 ± 0.5                                           2.1 ± 0.4                      
  CMMCs                                                                                                                                            
  Proportion (%)                                                Control                                             27.8 ± 3.5                     9.4 ± 3.7[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         32.4 ± 5.9                                          31.0 ± 6.4^b^                  
  Frequency (contractions/10 min)                               Control                                             9.0 ± 0.9                      2.5 ± 1.0[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         9.8 ± 2.2                                           6.0 ± 1.2^b^                   
  Speed (mm/s)                                                  Control                                             2.2 ± 0.3                      2.0 ± 0.5
  L‐NNA                                                         3.5 ± 0.8[a](#bph13646-note-0002){ref-type="fn"}    1.9 ± 0.5                      
  Short contractions                                                                                                                               
  Proportion (%)                                                Control                                             66.2 ± 2.4                     58.5 ± 6.9
  L‐NNA                                                         55.5 ± 3.9[a](#bph13646-note-0002){ref-type="fn"}   42.2 ± 6.2                     
  Frequency (contractions/10 min)                               Control                                             22.7 ± 2.4                     13.0 ± 2.0[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         17.6 ± 2.3                                          9.8 ± 1.9                      
  Speed (mm·s^−1^)                                              Control                                             1.6 ± 0.1                      0.8 ± 0.1[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         2.8 ± 0.6[a](#bph13646-note-0002){ref-type="fn"}    1.2 ± 0.2                      
  Distal anterograde short contraction frequency (per 10 min)   Control                                             14.5 ± 1.5                     6.4 ± 1.5[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         10.3 ± 1.5                                          4.8 ± 1.4                      
  Distal retrograde short contraction frequency (per 10 min)    Control                                             2.0 ± 0.6                      0.1 ± 0.1[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         1.0 ± 0.3                                           0.3 ± 0.1                      
  Fragmented contractions                                                                                                                          
  Proportion (%)                                                Control                                             6.0 ± 2.1                      32.1 ± 6.1[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         12.1 ± 3.1                                          26.8 ± 5.2                     
  Frequency (contractions/10 min)                               Control                                             2.1 ± 0.7                      6.2 ± 1.2[a](#bph13646-note-0002){ref-type="fn"}
  L‐NNA                                                         4.2 ± 1.2                                           6.0 ± 1.1                      

*P* \< 0.05 compared with sham‐control.

*P* \< 0.05 compared with oxaliplatin‐control.

### Colonic migrating motor complexes {#bph13646-sec-0030}

*In vivo* treatment with oxaliplatin was associated with a lower CMMC frequency than in sham‐treated preparations (*P* \< 0.05). Application of L‐NNA significantly increased the frequency of CMMCs in colons from oxaliplatin‐treated (*P* \< 0.05), but not sham‐treated mice (Figure [9](#bph13646-fig-0009){ref-type="fig"}A, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). The rate of rise of CMMCs was comparable between sham‐treated and oxaliplatin‐treated mice, but increased CMMC rate of rise following addition of L‐NNA was noted in the colons from sham (*P* \< 0.05), but not oxaliplatin‐treated animals (Figure [9](#bph13646-fig-0009){ref-type="fig"}B, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}).

![Effects of L‐NNA on CMMCs and short contractions. (A) The frequencies of CMMCs quantified in spatiotemporal maps from sham‐treated and oxaliplatin‐treated mice before and after L‐NNA application. (B) Speed of CMMCs in the colons from sham and oxaliplatin‐treated mice in both test conditions. \**P* \< 0.05, significantly different as indicated; *n* = 10 mice per group. (C) The frequencies of short contractions were quantified in spatiotemporal maps from sham and oxaliplatin‐treated mice before and after L‐NNA application. (D) Speed of all short contractions analysed before and after L‐NNA application. Changes in the frequency of distal anterograde (E) and retrograde (F) short contractions in the colons from sham and oxaliplatin‐treated mice in both test conditions. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 10 mice per group).](BPH-173-3502-g009){#bph13646-fig-0009}

### Short contractions {#bph13646-sec-0031}

Treatment with oxaliplatin resulted in a reduced frequency of short contractions in the colon (Figure [9](#bph13646-fig-0009){ref-type="fig"}C, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). L‐NNA had no effect on the frequency of short contractions in either group. The rate of rise of short contractions was twofold slower in colons from oxaliplatin‐treated mice (Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). L‐NNA significantly enhanced the propagation speed of short contractions in the sham (*P* \< 0.05), but not the oxaliplatin‐treated group. The frequency of short anterograde contractions in the distal region of the colon was significantly reduced in oxaliplatin‐treated animals compared with sham‐treated mice (Figure [9](#bph13646-fig-0009){ref-type="fig"}E, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). Short contractions initiated in the distal colon were also found to travel in a retrograde direction. These retrograde short contractions occurred at a significantly reduced frequency in colons from oxaliplatin‐treated mice compared to sham‐treated mice (Figure [9](#bph13646-fig-0009){ref-type="fig"}F, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). L‐NNA had no effects on anterograde or retrograde short distal contractions in either group.

### Fragmented contractions {#bph13646-sec-0032}

These were defined as incomplete contractions occurring simultaneously rather than propagating over the length of the colon (Figure [10](#bph13646-fig-0010){ref-type="fig"}A). The frequency of fragmented contractions was significantly higher in oxaliplatin‐treated than in sham‐treated mice (Figure [10](#bph13646-fig-0010){ref-type="fig"}B, Table [1](#bph13646-tbl-0001){ref-type="table-wrap"}). Application of L‐NNA did not affect the frequency of fragmented contractions in either oxaliplatin‐treated or sham‐treated mice.

![Effects of L‐NNA on fragmented contractions and colonic faecal content. (A) Fragmented contractions were defined as interrupted contractions consisting of period(s) of relaxation (arrow) and simultaneously occurring contractions (arrowheads). The frequency (B) of fragmented contractions in the colon from sham and oxaliplatin‐treated mice before and after L‐NNA application. (C) Wet weight of faecal pellets measured immediately upon pellet expulsion; dry weight of faecal pellets measured after 72 h of dehydration at room temperature. (D) Faecal water content calculated as the difference between the wet weight and dry weight. (E) Total number of faecal pellets along the entire length of the colon counted in freshly excised intact colons. Data presented as mean ± SEM. \**P* \< 0.05, significantly different as indicated; *n* = 10 mice per group.](BPH-173-3502-g010){#bph13646-fig-0010}

Colonic faecal content {#bph13646-sec-0033}
----------------------

To define the clinical symptoms resulting from the altered patterns of colonic motor activity, fresh faecal pellets were collected from both sham and oxaliplatin‐treated mice and faecal water content was calculated as the difference between wet and dry pellet weight (Figure [10](#bph13646-fig-0010){ref-type="fig"}C,D). The fresh pellets (wet weight) from oxaliplatin‐treated mice weighed significantly less than those of sham‐treated mice (Figure [10](#bph13646-fig-0010){ref-type="fig"}C). After dehydration, the dry weight of pellets from sham‐treated mice and from oxaliplatin‐treated mice were not different (Figure [10](#bph13646-fig-0010){ref-type="fig"}C). Thus, the water content was significantly lower in pellets collected from oxaliplatin‐treated mice than in those collected from sham‐treated mice (Figure [10](#bph13646-fig-0010){ref-type="fig"}D). Total number of pellets within the entire length of excised colons from oxaliplatin‐treated mice was significantly higher than the number in sham‐treated mice (Figure [10](#bph13646-fig-0010){ref-type="fig"}E).

Discussion {#bph13646-sec-0034}
==========

This study is the first to examine the role of oxidative stress *in vivo* on enteric neurons of the colon that may be involved in mechanisms underlying colonic dysmotility associated with oxaliplatin treatment. The results show that mitochondrial superoxide and nitrated protein levels are significantly increased in the myenteric and submucosal ganglia after oxaliplatin treatment. Mitochondrial depolarisation and increased mitochondrial permeability leading to release of cytochrome *c* from mitochondria were increased in myenteric ganglia in the colon from oxaliplatin‐treated mice. This presumably led to increased expression of an 'executioner' caspase‐3 in both the submucosal and myenteric ganglia in the colon preparations from oxaliplatin‐treated mice. Oxidative stress and neuronal apoptosis resulted in functional changes in the colon (increased nitrergic neuromuscular transmission, decreased smooth muscle tone, changes in the patterns and parameters of colonic motility) leading to symptoms of constipation in mice after long‐term treatment with oxaliplatin.

Oxaliplatin‐induced oxidative stress and neuronal apoptosis {#bph13646-sec-0035}
-----------------------------------------------------------

Oxidative stress in enteric neurons following oxaliplatin treatment was shown by increased mitochondrial superoxide and translocation of nitrated proteins in submucosal and myenteric plexuses as well as the increase in expression of iNOS observed in our study. Mitochondria are responsible for most of the ROS burden under both normal and pathological conditions. The increased level of mitochondrial superoxide observed in enteric neurons is consistent with findings showing increased mitochondrial ROS in neuronal cultures from dorsal root ganglia of oxaliplatin‐treated rats (Kelley *et al.,* [2014](#bph13646-bib-0028){ref-type="ref"}). Inhibition of mitochondrial electron transport chain complexes I and III involved in mitochondrial ROS formation improves sensory hyperalgesia in a rat model of peripheral neuropathy induced by another platinum‐based chemotherapeutic drug, cisplatin (Joseph and Levine, [2009](#bph13646-bib-0027){ref-type="ref"}). Mitotoxicity affecting mitochondrial respiration and ATP production were found in sciatic nerve from oxaliplatin‐treated rats and linked to oxaliplatin‐induced peripheral neuropathy (Zheng *et al.,* [2011](#bph13646-bib-0065){ref-type="ref"}), which could be prevented by peroxynitrite decomposition catalyst (Janes *et al.,* [2013](#bph13646-bib-0026){ref-type="ref"}). Thus, reduction of oxidative stress‐related biomarkers in peripheral neurons may be a promising avenue for alleviation of chemotherapy‐induced neuropathies.

Oxaliplatin‐induced mitochondrial damage has also been proposed as a potential mechanism leading to activation of NOS (Areti *et al.,* [2014](#bph13646-bib-0004){ref-type="ref"}). The direct toxicity of NO can be greatly enhanced by reacting with superoxide to form peroxynitrite, which modifies tyrosines in proteins to create nitrotyrosines. Nitration of structural proteins can have major pathological consequences, but can also be an indicator of oxidative stress (Beckman and Koppenol, [1996](#bph13646-bib-0005){ref-type="ref"}). We identified translocation of nitrated proteins in both submucosal and myenteric plexuses of the colon from oxaliplatin‐treated mice. Translocation of nitrotyrosine has been previously found in myenteric neurons following ischaemia and reperfusion in mice (Rivera *et al.,* [2011b](#bph13646-bib-0043){ref-type="ref"}) and induction of colitis in rats (Zingarelli *et al.,* [2003](#bph13646-bib-0066){ref-type="ref"}); both of which were correlated with increases in NO and ROS. The increased level of iNOS observed in the LMMP preparations in our study probably leads to increased production of NO contributing to the accumulation of nitrotyrosine in enteric neurons. Although nitration can be used as an indirect measure of peroxynitrite, accumulation of nitrotyrosine itself is correlated with increased susceptibility to NO‐induced apoptosis (Savidge, [2011](#bph13646-bib-0050){ref-type="ref"}). Accumulation of nitrotyrosine has been linked to protein misfolding, mitochondrial dysfunction and neuronal degeneration (Nakamura and Lipton, [2008](#bph13646-bib-0035){ref-type="ref"}). Increased ROS and concurrent oxidative stress are linked to damage in various cellular components, and neuronal death (Wei *et al.,* [2000](#bph13646-bib-0063){ref-type="ref"}).

One of many by‐products of oxaliplatin metabolism is oxalate and increases in oxalate levels trigger intracellular Ca^2^ ^+^ influx (Webster *et al.,* [2005](#bph13646-bib-0062){ref-type="ref"}). Increased cytoplasmic Ca^2^ ^+^ activates nNOS, potentially leading to excessive NO production as well as activating the release of cytochrome *c* (Yagihashi *et al.,* [2000](#bph13646-bib-0064){ref-type="ref"}). Release of JC‐10‐labelled cytochrome *c* diffusing out of the mitochondria as a result of mitochondrial depolarisation and increased permeability was observed in both submucosal and myenteric neurons in our study. The increase in superoxide and NO production may be a direct consequence of the loss of mitochondrial cytochrome *c* (Düssmann *et al.,* [2003](#bph13646-bib-0070){ref-type="ref"}). The rate of superoxide production is linked to the magnitude of mitochondrial membrane potential and mitochondrial permeability (Brand *et al.,* [2004](#bph13646-bib-0007){ref-type="ref"}). The magnitude of mitochondrial depolarisation dictates cytochrome *c* release and hence the activation of apoptosis. Modest mitochondrial depolarisation is transient and reversible, and has been found to be protective against moderate tissue injury (Schweizer and Richter, [1994](#bph13646-bib-0051){ref-type="ref"}; Gottlieb *et al.,* [2003](#bph13646-bib-0021){ref-type="ref"}). Apoptotic cells exhibit distinctive biochemical features, including the presence of specific cleaved proteins (Hengartner, [2000](#bph13646-bib-0025){ref-type="ref"}). Caspase‐3 is a key effector or 'executioner' caspase, cleaving various substrates to cause the morphological and biochemical changes seen in apoptotic cells (Slee *et al.,* [2001](#bph13646-bib-0053){ref-type="ref"}; Elmore, [2007](#bph13646-bib-0018){ref-type="ref"}; McIlwain *et al.,* [2013](#bph13646-bib-0032){ref-type="ref"}). Our results are consistent with previous studies using caspase‐3 antibody, which found both intracellular immunoreactivity and detected extracellular aggregates of apoptotic debris outside neuronal cells (Pasinelli *et al.,* [2000](#bph13646-bib-0036){ref-type="ref"}). Due to the fact that the half‐life of activated caspase‐3 is 8 h, it is difficult to detect significant amounts of activated caspase 3 within enteric ganglia. It is possible that the activation of caspase‐3 might have occurred at the earlier stages of oxaliplatin treatment resulting into neuronal apoptosis; this would explain both neuronal loss and presence of apoptotic debris observed in our study at day 14. Increased expression of caspase‐3 observed in our study is indicative of oxaliplatin‐induced apoptosis which resulted in 43% loss of myenteric neurons in the distal colon, 16% of myenteric neurons in the proximal colon and 30% of submucosal neurons in the distal colon. Similarly, oxaliplatin treatment induced 12% loss of myenteric and 21% submucosal neurons in the mouse ileum at day 14 (Robinson *et al.,* [2016](#bph13646-bib-0047){ref-type="ref"}). Although oxaliplatin causes neuronal death in all studied intestinal regions, it seems that neurons in the distal colon are more susceptible to oxaliplatin‐induced damage than neurons in the proximal colon and ileum. There may be many reasons for these regional differences, but it should be noted that the proportion of the nNOS‐IR neurons was significantly increased in the distal, but not proximal colon, consistent with a role for NO in oxaliplatin‐induced enteric neuronal loss. Moreover, repeated *in vivo* oxaliplatin administration induces decreases in glial fibrillary acidic protein‐IR enteric glia, contrasting with increases in s100β‐IR enteric glial cells in both the myenteric and submucosal ganglia at day 14 after commencement of treatment (Robinson *et al.,* [2016](#bph13646-bib-0047){ref-type="ref"}).

Changes in neuromuscular transmission and smooth muscle tone {#bph13646-sec-0036}
------------------------------------------------------------

NO released from nNOS expressing inhibitory motor neurons supplying the intestinal smooth muscles is an integral inhibitory neurotransmitter in the gastrointestinal tract (Lecci *et al.,* [2002](#bph13646-bib-0030){ref-type="ref"}; Takahashi, [2003](#bph13646-bib-0057){ref-type="ref"}). nNOS produces basal levels of NO to maintain the hyperpolarised state of the circular muscle cells leading to physiological tonic inhibition of the intestine ( Daniel *et al.,* [1994](#bph13646-bib-0013){ref-type="ref"}). Excessive NO production and consequent nitrosylation has been linked to inhibition of dynamin‐related protein 1, resulting in synaptic impairment and disruption to synaptic transmission (Savidge, [2011](#bph13646-bib-0050){ref-type="ref"}). In our study, intracellular recordings from colonic circular muscles revealed changes in neuromuscular transmission with an increase in amplitude of NO‐mediated sIJPs potentials in the oxaliplatin‐treated group. No changes in ATP‐mediated fIJPs or ACh‐mediated EJPS were observed. These results differ from findings in inflamed guinea pig colon where oxidative stress leads to reduced purinergic neuromuscular transmission (Roberts *et al.,* [2013](#bph13646-bib-0044){ref-type="ref"}). This may be due to differences in mechanisms of oxaliplatin‐induced neuronal damage from inflammation‐induced enteric neuropathy. Oxaliplatin exerts its cytotoxic effects via direct binding to nuclear and mitochondrial DNA and formation of platinum‐DNA adducts (Graham *et al.,* [2000](#bph13646-bib-0022){ref-type="ref"}; Goodisman *et al.,* [2006](#bph13646-bib-0020){ref-type="ref"}). Direct mitochondrial damage leads to excessive NO production and activation of apoptotic cascades as discussed above.

Direct oxaliplatin toxicity and increased NO signalling alter the functions of colonic circular muscles. The relaxation evoked by the NO donor, SNP, was reduced by about 50% in the distal colon from oxaliplatin‐treated mice. The baseline diameter of the distal colon was greater in oxaliplatin‐treated animals than in sham‐treated mice suggesting a reduction in the colonic muscle tone after oxaliplatin treatment. This was reversed by application of L‐NNA inhibiting all NOS isoforms including iNOS, which was increased in longitudinal muscle‐myenteric neuron preparations after oxaliplatin treatment. The reduced smooth muscle tone as well the reduced response to the NO donor could be a result of the relatively higher inhibitory activity compared with the excitatory due to the increased proportion of nNOS neurons observed in oxaliplatin‐treated mice. The reduction in muscle thickness that we observed after oxaliplatin treatment may also contribute to a reduction in muscle tone. Decreased basal tone and, thus, a larger resting diameter of the distal colon compromised the ability of smooth muscles to further relax. Similar findings have been observed following intestinal inflammation where smooth muscle relaxation in response to a NO donor was decreased (Van Bergeijk *et al.,* [1998](#bph13646-bib-0058){ref-type="ref"}; Rajagopal *et al.,* [2015](#bph13646-bib-0039){ref-type="ref"}). This compromised ability to relax was in part attributed to iNOS‐mediated protein nitrosylation (Rajagopal *et al.,* [2015](#bph13646-bib-0039){ref-type="ref"}).

Oxaliplatin‐induced changes in colonic motility {#bph13646-sec-0037}
-----------------------------------------------

To investigate the role of NO in colonic dysmotility resulting from oxaliplatin treatment, we performed experiments with and without application of the NOS inhibitor, L‐NNA, and analysed phases of contraction in various parts of the colon, overall colonic motor patterns and parameters of specific types of motor activity.

Alterations in the basal tone of the colon and augmented nitrergic transmission may be attributed to increased NO release providing enhanced inhibitory input to the smooth muscle and altering colonic contractile patterns. Analysis of spatiotemporal maps revealed reductions in the proportion and frequency of CMMCs as well as in frequency and speed of short contractions in the distal colon from oxaliplatin‐treated mice. Anterograde and retrograde short contractions were observed in the distal colon of both sham and oxaliplatin‐treated mice. Both types of short contractions were significantly reduced in the distal colon after oxaliplatin treatment. In contrast, the proportion and frequency of fragmented contractions were greater in colons from oxaliplatin‐treated mice. These findings are consistent with previous studies demonstrating inhibition of CMMCs in the colon of oxaliplatin‐treated mice (Wafai *et al.,* [2013](#bph13646-bib-0061){ref-type="ref"}) and inhibition of intestinal transit in cisplatin‐treated rats (Vera *et al.,* [2011](#bph13646-bib-0059){ref-type="ref"}).

Previous studies using NOS inhibitors have established a role of NO in the pathophysiology of gastrointestinal functional disorders (Rivera *et al.,* [2011a](#bph13646-bib-0042){ref-type="ref"}). NO is a primary regulator of complex intestinal motor patterns and increased NO release can disrupt CMMCs (Sarna *et al.,* [1993](#bph13646-bib-0049){ref-type="ref"}; Rodriguez‐Membrilla *et al.,* [1995](#bph13646-bib-0048){ref-type="ref"}; Castro *et al.,* [2012](#bph13646-bib-0010){ref-type="ref"}). In our study, application of the NOS inhibitor, L‐NNA, restored the proportion and frequency of CMMCs in oxaliplatin‐treated mice. NOS inhibition increased the rate of rise of all types of contractions (CMMCs, short and fragmented) in the colons from sham‐treated, but not oxaliplatin‐treated mice. This is consistent with previous studies reporting increased speed of contraction induced by L‐NNA in control mice (Rodriguez‐Membrilla *et al.,* [1995](#bph13646-bib-0048){ref-type="ref"}). Inhibition of NOS by L‐NNA did not affect short and fragmented contractions in colons from oxaliplatin‐treated mice. This suggests that the augmented proportion and frequency of fragmented contractions and reduced frequency of short contractions observed in oxaliplatin‐treated mice are not due to increased NO release, but can be attributed to either disruption of enteric neural pathways or a direct effect on colonic smooth muscle function. Colonic dysmotility was associated with reduction in faecal water content and increase in number of pellets in the colon providing evidence that oxaliplatin‐treated mice had constipation.

In conclusion, oxaliplatin treatment induces severe gastrointestinal side‐effects such as nausea, vomiting, constipation and diarrhoea, which account for dose limitations and/or cessation of treatment. These symptoms can persist up to 10 years after the treatment has been ceased (Denlinger and Barsevick, [2009](#bph13646-bib-0016){ref-type="ref"}). Oxidative stress has been suggested as a potential mechanism underlying platinum neurotoxicity (Di Cesare Mannelli *et al.,* [2012](#bph13646-bib-0017){ref-type="ref"}). Our study is the first providing evidence that oxidative stress is a key player in enteric neuronal death, changes in intestinal smooth muscle tone and neuromuscular transmission underlying colonic dysmotility and leading to chronic constipation associated with oxaliplatin treatment. Further studies elucidating mechanisms of oxaliplatin‐induced oxidative stress are warranted in order to develop strategies to alleviate gastrointestinal side‐effects of chemotherapy and achieve more effective anti‐cancer treatment.
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